Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review

Chemotherapy combined with immunotherapy has significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), and neoadjuvant immunotherapy combined with chemotherapy has emerged as the standard treatment for those with resectable non-small cell lung cancer (NSCLC)....

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-01, Vol.14, p.1272450
Main Authors: Mei, Ting, Wang, Ting, Lei, Chuanfen, Jiang, Dan, Zhou, Qinghua
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung - drug therapy
case report
Drug-Related Side Effects and Adverse Reactions
Humans
Immune Checkpoint Inhibitors
Immunology
immunotherapy
Lung Neoplasms - drug therapy
Neoadjuvant Therapy
Pathologic Complete Response
pathological complete response
serplulimab
small cell lung cancer
Small Cell Lung Carcinoma - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chemotherapy combined with immunotherapy has significantly improved survival in patients with extensive-stage small cell lung cancer (ES-SCLC), and neoadjuvant immunotherapy combined with chemotherapy has emerged as the standard treatment for those with resectable non-small cell lung cancer (NSCLC). However, the potential benefits of surgery following neoadjuvant immunotherapy combined with chemotherapy in locally advanced SCLC remain unclear. Herein, we report a patient diagnosed with stage IIIB SCLC, who was administered five cycles of neoadjuvant serplulimab combined with chemotherapy followed by surgery, and subsequently achieved a pathologic complete response (pCR). Within a follow-up duration of six months, the patient displayed neither recurrence nor metastasis and experienced no treatment-related adverse reactions of any grade. Based on this case, for locally advanced SCLC, neoadjuvant serplulimab combined with chemotherapy followed by surgery may present an effective, safe, and potentially curative treatment strategy. Nonetheless, further prospective studies are needed to verify our findings.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1272450